Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's ...
The reason why is because while several analysts downgraded the stock on the back of the data released of povorcitinib for the treatment of patients with Hidradenitis Suppurativa [HS], I believe that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback